Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study
- 898 Downloads
This study was conducted in order to characterize the prevalence of falls and functional impairments (FIs) and their association with chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors.
We analyzed baseline assessments from a phase III RCT in cancer survivors with self-reported CIPN scores of >4 out of 10. Patients completed the EORTC QLQ-CIPN-20 for neuropathy and reported falls in the previous 3 months. FIs were defined using the Activities of Daily Living subsection of the Vulnerable Elder’s Scale. Associations of baseline characteristics and CIPN with falls and FIs were examined using logistic regression.
Of 421 patients, 11.9 % experienced recent falls and 26.6 % reported FIs. Motor neuropathy was the only factor associated with falls (OR = 1.127, p = 0.01). Factors associated with FIs included non-white race (OR = 0.335 white relative to non-white, 0.781, p = 0.01) and greater motor neuropathy scores (OR = 1.262, p < 0.0001).
CIPN, primarily motor, is associated with falls and FIs. Future prospective research should investigate the ability of motor neuropathy severity to predict falls.
KeywordsFalls Functional impairments Neuropathy Cancer survivors
This work was funded by the National Cancer Institute (R25CA10618 and U10CA37420). The work was also funded by a generous gift from Sandy Lloyd to the Geriatric Oncology Program at the James Wilmot Cancer Center. The study sponsors had no role in the study design, data collection, or data interpretation. We thank the patients, clinicians, and researchers of the University of Rochester Community Clinical Oncology Program who contributed to this study.
Conflict of interest
The authors have no conflicts of interest to disclose. We have full control of all primary data and agree to allow the journal to review the data if requested.
- 9.Lisa Sprod SGM, Lin Fan, Michelle Christine Janelsins, Luke Joseph Peppone, Kavita Dayal Chandwani, Gary R. Morrow, Karen Michelle Mustian (2012) Physical activity participation and functional limitations in geriatric cancer survivors. J Clin Oncol (suppl; abstr 9009)Google Scholar
- 15.Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M (2007) A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109(4):802–810. doi: 10.1002/cncr.22495 PubMedCrossRefGoogle Scholar
- 16.Luciani A, Ascione G, Bertuzzi C, Marussi D, Codeca C, Di Maria G, Caldiera SE, Floriani I, Zonato S, Ferrari D, Foa P (2010) Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 28(12):2046–2050. doi: 10.1200/JCO.2009.25.9978 PubMedCrossRefGoogle Scholar
- 17.Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139. doi: 10.1016/j.ejca.2005.02.012 PubMedCrossRefGoogle Scholar
- 18.Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462. doi: 10.1093/annonc/mds329 PubMedCrossRefGoogle Scholar
- 19.Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL (2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Canc 19(6):833–841. doi: 10.1007/s00520-010-0911-0 CrossRefGoogle Scholar
- 22.SEER Cancer Statistics. (2011) National Cancer Institute. http://seer.cancer.gov/statfacts/html/all.html. Accessed Jan 2012
- 26.Prevention CfDCa (2010) Falls among older adults: an overview. http://www.cdc.gov/HomeandRecreationalSafety/Falls/adultfalls.html. Accessed Jan 2012